Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

POINT OF CARE DEVICE FOR VITAMIN D DEFICIENCY MONITORING

Project description

Improved diagnostics could shed more light on vitamin D deficiency

Mounting evidence now supports important roles of vitamin D in extraskeletal tissues and how vitamin D inadequacy can impact conditions ranging from cancer to cardiovascular disease. In addition, the amounts required for health are likely higher than previously thought. At the same time, vitamin D deficiency or insufficiency is increasing. Although estimates vary, evidence suggests that more than one billion people globally (more than 10 % of the population) are vitamin D deficient or insufficient. OSAvit-D is developing a cost-effective point-of-care diagnostic device for widespread screening during outpatient visits and in the field. This will improve and enable early detection and treatment of the potentially harmful and increasingly prevalent vitamin D deficiency.

Objective

OSASEN is a young technological SME focused on the development of novel biosensors for healthcare (Point of Care-PoC devices), addressing priority needs in healthcare diagnostics and/or therapies monitoring for the benefit of patients, providing affordable systems with unique features that meet specific well identified requirements in healthcare. OSASEN has recently identified a healthcare need in relation with prevention, treatment and monitoring of Vitamin D (VitD) deficiency. VitD (1,25-DihydroxyvitaminD) is considered a multipurpose steroid hormone that in human plays an essential role in multiple aspects, being its primary role to participate in the regulation of metabolism of calcium and phosphorous. VitD deficiency is evident throughout the European population at a prevalence of 13% (FP7-613977-ODIN project), a rate that is a matter of concern. People over 50 have an increased risk of vitamin D deficiency with consequent bone loss risk leading to osteoporosis and fractures. Emerging evidence has shown that VitD administration improves muscle performance and reduces falls in VitD deficient older adults. Other populations of higher risk for VitD deficiency are children, pregnant and lactating women and patients with digestive disorders, among others. VitD deficiency is also associated with increased risk of cancer, cardiovascular disease, infections, and autoimmune diseases. For example, several studies have shown that VitD levels are lower in Multiple Sclerosis patients, and monitoring and VitD supplementation to them is highly recommended. In this context, OSASEN has identified the opportunity to develop a novel PoC device for the quantification of VitD in blood or urine based on lateral flow (LF) immunoassay, combined with electrochemical detection on screen printed electrodes (SPEs). For doing so, it is necessary to incorporate an expert in LF immunoassays and antibody selection, conjugation, handling & stabilization to OSASEN’s team.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

CSA - Coordination and support action

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) H2020-INNOSUP-2018-2020

See all projects funded under this call

Coordinator

BIOLAN HEALTH SL
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 100 687,50
Address
C/ LAIDA BIDEA EDIFICIO 409 DEL COMPLEJO PARQUE TECNOLOGICO DE BIZKAIA
48170 ZAMUDIO
Spain

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Noreste País Vasco Bizkaia
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 100 687,50
My booklet 0 0